Diabetes

Nisa Maruthur, MD, MHS, a primary care physician and consensus report coauthor, discusses elements of the most effective care for patients with type 2 diabetes (T2D).

Dr Maruthur, a PCP and coauthor for the new ADA/EASD consensus report on T2D, says that's why this report includes the "tips on implementation" sections.

Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.

As long as the role of social determinants of health in T2D is not prioritized, care for these patients will remain poor and outcomes will not improve, says consensus report author.

When modeled as first-line therapy vs metformin, treatment benefit was significantly outweighed by cost for both classes.

Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.

A T2D diagnosis in adults aged 50 to 59 years vs 60 to 69 years or ≥70 years was linked to significantly increased risk for cardio- and cerebrovascular disease and all-cause mortality.

Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

Multimorbidity was associated with a 63% increased risk for dementia among adults older than age 60 years followed for up to 15 years.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

New survey findings suggest the need for more in-depth conversations with patients about benefits and harms of newer oral therapies for type 2 diabetes.

Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.

Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.

Youth newly diagnosed with T2D also were metabolically sicker, with higher HbA1c, serum glucose levels, and BMI at presentation.

Phase II clinical trial shows a fixed dose combination of semaglutide/cagrilintide reduces HbA1c and weight much better than either drug alone.

The woman is in her mid-fifties, diarrhea has been persistent for 10 days and BUQ pain for 2 days. What does the CT show? What's your diagnosis?

Analysis of 224 000 type 2 diabetes patients over 2 decades suggests the need for "revised care pathways" that better reflect the myriad causes of persistent morbidity.

The USPSTF guidance supports shared decision making with patients without CVD risk factors who may benefit from behavioral counseling on diet and physical activity.

Food consumption confined to a 10-hour period for adults with T2D led to increased time in range and lowered nocturnal and fasting glucose.

The GLP-1 RA given once weekly to T2D patients with hyperglycemia not controlled by diet and exercise lowered HbA1c to ≤6.5% in approximately half the study population.